Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Fulcrum Therapeutics Inc (FULC)

Fulcrum Therapeutics Inc (FULC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Fri May 8, 3:30PM CDT

CAMBRIDGE, Mass., May 08, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives...

FULC : 5.91 (-2.96%)
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026 GlobeNewswire - Mon Apr 27, 6:00AM CDT

― Presented positive clinical data for pociredir, demonstrating robust and rapid fetal hemoglobin (HbF) induction, improvements in markers of hemolysis and anemia, and encouraging trends in vaso-occlusive...

FULC : 5.91 (-2.96%)
Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors GlobeNewswire - Mon Apr 27, 5:55AM CDT

CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Fulcrum) (NASDAQ: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules that improve...

FULC : 5.91 (-2.96%)
Can Fulcrum Therapeutics Translate Pociredir Trial Data Into Revenue Momentum? Barchart - Sun Apr 26, 4:00PM CDT

Barchart Research What to Expect from FULC Earnings FULC Generated April 24, 2026 Current Price $7.84 EPS Estimate $$-0.31 Consensus Rating Moderate Buy Average Move 9.72% Can Fulcrum Therapeutics Translate...

FULC : 5.91 (-2.96%)
Can Fulcrum Therapeutics Translate Pociredir Trial Data Into Revenue Momentum? Barchart - Sat Apr 25, 4:00PM CDT

Barchart Research What to Expect from FULC Earnings FULC Generated April 24, 2026 Current Price $7.84 EPS Estimate $$-0.31 Consensus Rating Moderate Buy Average Move 9.72% Can Fulcrum Therapeutics Translate...

FULC : 5.91 (-2.96%)
Can Fulcrum Therapeutics Translate Pociredir Trial Data Into Revenue Momentum? Barchart - Fri Apr 24, 4:02PM CDT

Barchart Research What to Expect from FULC Earnings FULC Generated April 24, 2026 Current Price $7.84 EPS Estimate $$-0.31 Consensus Rating Moderate Buy Average Move 9.72% Can Fulcrum Therapeutics Translate...

FULC : 5.91 (-2.96%)
Fulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, April 27, 2026, at 8:00 a.m. ET GlobeNewswire - Mon Apr 20, 7:00AM CDT

CAMBRIDGE, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules...

FULC : 5.91 (-2.96%)
MedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle Cell Disease  GlobeNewswire - Thu Mar 19, 7:00AM CDT

CAMBRIDGE, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- MedicAlert Foundation, the leading nonprofit providing medical IDs and emergency medical information services, Sickle Cell Disease Association of...

FULC : 5.91 (-2.96%)
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Fri Mar 6, 3:30PM CST

CAMBRIDGE, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives...

FULC : 5.91 (-2.96%)
Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference GlobeNewswire - Tue Mar 3, 7:30AM CST

CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules...

FULC : 5.91 (-2.96%)

Barchart Exclusives

IBM Stock Leads Mega-Cap Stock Decliners as Market Volatility Triggers Steep Selloff. That Doesn’t Tell You the Whole Story. Barchart - Tue May 19, 3:56PM CDT
IBM stock has shed 25% in 2026, topping mega-cap decliners. Strong earnings haven't stopped the slide. Here's what investors need to know. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.